research report · MRK

Merck & Co., Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 4, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 4, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Stable

little material change

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Merck's underlying business is little changed, and the company is borrowing to replace Keytruda. Third-quarter sales rose 5% to $18.1B, but about $550M of that came from the timing of U.S. purchases. The raised full-year range implies fourth-quarter sales of $15.8–16.3B, below the $16.4B of a year earlier (my calculation). Cash generation is the strength: nine-month operating cash flow of $15.8B covers dividends and buybacks. Debt, meanwhile, rose to $53.8B from $41.4B a year earlier to buy pipeline assets whose payoff is years away. The outcome turns on whether new launches can outrun Keytruda's erosion from late 2028; this quarter shows progress, not proof.

what changed this quarter

  • Results: Sales were $18,085M vs $17,276M (+5%; +4% excluding currency). GAAP earnings per share (EPS) were $2.04 vs $2.32. Non-GAAP EPS was $2.49 vs $2.58, including a $0.12 charge for the SciBrunch license.
  • Guidance: Sales of $66.8–67.3B (was $66.3–67.3B). Non-GAAP EPS of $2.77–2.82 (was $2.66–2.76), which now absorbs the SciBrunch charge. Tax rate of 32–33% (was 35–36%).
  • Deals and funding: Terns ($6.8B, May), TARGAN ($647M, July) and SciBrunch ($400M upfront, September), plus $6.0B of new notes in May.
  • Lost U.S. exclusivity: Januvia/Janumet in May and Bridion in July. Bridion sales fell to $144M from $439M.
  • Rulings: On August 24 a court granted summary judgment to the government in Merck's suit against Inflation Reduction Act (IRA) drug price setting. On October 7 a Dutch injunction blocked subcutaneous Keytruda in several European markets.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Reported growth overstates the core business
  • Keytruda's growth rests on a contested subcutaneous switch
  • Profit is falling by design as spending and interest outrun sales
  • The pipeline is being bought on credit, with returns years out

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what MRK files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on MRK say?” Add Viridis to Claude, or to ChatGPT.